ANT308 is an antagonist of the vasoactive intestinal peptide (VIP receptor). It significantly enhances T cell activation and proliferation. By inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin, ANT308 suppresses melanoma cell migration and metastasis while inducing apoptosis. This compound is useful for research in acute myeloid leukemia (AML) and uveal melanoma (UVM).

ANT308 significantly increases the expression of CD69 and Ki67 in CD4+ and CD8+ T cells at concentrations of 1-10 μM over 48 hours. It reduces the viability of B16F10 and HT-144 cells in a dose-dependent manner at 0.1-10 μM over 72 hours. Without ANT308 (0 μM) for 72 hours, there is a reduction in the S phase cell population and induction of apoptosis in B16LS9 and Mel 290 cells. At 10 μM for 72 hours, ANT308 markedly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines. Furthermore, over 72 hours, ANT308 decreases the expression of MCAM and N-cadherin by inhibiting VIP-VPAC2 signaling.

ANT308, when administered subcutaneously at 6 nmol once daily for 10-14 days, significantly prolongs the survival of mice and reduces tumor burden in an AML model. Furthermore, ANT308 (100 μg/100 μL PBS, subcutaneously, twice daily for 10 days) decreases the number and size of hepatic metastases following intraocular or subcutaneous melanoma cell injections in mice and shows a tendency to reduce the tumor volume at the primary sites.